Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Okta, Inc. (OKTA) Price & Performance

Cronos Group IncTrade
Okta, Inc.Trade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Okta, Inc. — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Okta, Inc. trades at $232.13 (market cap $38.50B). The key difference: Okta, Inc. is far larger — about 32.6× Cronos Group Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Okta, Inc. for 44 Days on average.

CRONOKTA
Market Cap
$1.18B$38.50B
Volume
968,0372,479,621
Sector
HealthTechnology
52-Week High
$3.55$220.21
52-Week Low
$2.30$62.93
Typical Hold Time
22 Days44 Days
Enterprise Value
$387.62M$36.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.23, down 0.31% with a bearish technical signal. Recent earnings show volatility with Q2 2026 beating expectations ($0.09 vs $0.01) but Q4 2025 missing. Revenue grew from $118M (2024) to $147M (2025), though net income turned negative at -$9M. The company maintains strong liquidity with $827M cash and no debt, highlighted in recent investor day presentations.

Outlook is mixed: analyst consensus leans Hold (60%) with cautious optimism on international expansion and margin improvements. Key risks include sustained negative cash flow (-$67M in 2025) and competitive pressures. Upside hinges on execution of growth initiatives in Canada and Europe, with profitability projections for 2026.

Okta, Inc.

OKTA's stock trades at $232.13, up 6.48% in the last 24 hours, reflecting strong momentum. The technical outlook is bullish, with the price near resistance at $232. Recent earnings beats and a strategic focus on AI agent security, highlighted at the Oktane 2026 conference, support positive sentiment. However, valuation ratios like a P/E of 132.66 and P/S of 12.74 indicate a premium, while the company has only recently achieved profitability with a net income margin of 1.07% in 2025.

The outlook is cautiously optimistic, driven by revenue growth and AI positioning, but high valuation and competitive pressures pose risks. Analyst consensus is strongly bullish with a 73.58% buy rating, though the current price exceeds the consensus target of $201.30, suggesting near-term consolidation may occur. Investors should weigh growth potential against premium multiples and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRON

No sentiment data available yet.

OKTA
43% Buy57% Sell
Avg holding period · 44 Days

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON →

About Okta, Inc.

Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.

Read more on OKTA →